Oncotarget · 2017 · 64 citations · 24 references
MedicineOncologyPharmacologyBreast OncologyEndocrine PharmacotherapyMetastasisBreast Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerAromatase InhibitorsHormone Receptor - Positive Breast CancerHormone Receptor Positive Metastatic DiseaseHormone Receptor-positive DiseaseMetastatic Breast Cancer TreatmentMtor InhibitionMtor SignalingPhase Ii Clinical Trials
// Yannan Zhao 1, * , Chengcheng Gong 1, * , Zhonghua Wang 1 , Jian Zhang 1 , Leiping Wang 1 , Sheng Zhang 1 , Jun Cao 1 , Zhonghua Tao 1 , Ting Li 1 , Biyun Wang 1 and Xichun Hu 1 1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China * These authors have contributed equally to this work Correspondence to: Biyun Wang, email: wangbiyun0107@hotmail.com Xichun Hu, email: xchu2009@hotmail.com Keywords: metastatic breast cancer, hormone receptor positive, endocrine therapy, metformin, pre-treated Received: April 18, 2017 Accepted: July 19, 2017 Published: August 24, 2017 ABSTRACT Background: Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer. Metformin has been shown to inhibit mTOR pathway, with more favorable safety profile, leading to this hypothesis-generating trial to assess whether metformin enhances the efficacy of aromatase inhibitors. Methods: 60 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer were randomly assigned 1:1 to aromatase inhibitor (exemestane 25mg/d or letrozole 2.5mg/d depending on the most recent treatment) plus metformin (0.5g bid, orally) or placebo. The primary endpoint was PFS, and secondary endpoints were objective response rate, clinical benefit rate, overall survival and safety. Results: Median PFS was 4.7 months in the combination group and 6.0 months in the control group (hazard ratio, 1.2; 95% confidence interval [CI], 0.7 to 2.1; P =0.48). ORR was 6.7% in the combination group and 0% in the control group (odds ratio for ORR not available; P =0.99), and CBR was 33.3% and 50.0%, respectively (OR for CBR 0.5; 95% CI, 0.2 to 1.4; P=0.15). No significant difference in overall survival was observed between the combination and control groups (median OS, 30.9 vs. 32.4 months; P = 0.81). Subgroup analyses didn’t find any specific population favoring the combination treatment. No substantial difference in incidence or severity of adverse events was seen between the two treatment groups. Conclusion: This randomized phase II clinical trial failed to show an improved efficacy with the addition of metformin to endocrine therapy, although with excellent tolerability.
24
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +9
Metformin and reduced risk of cancer in diabetic patients
Josie Evans, Louise A. Donnelly, Alistair Emslie‐Smith et al. · BMJ · 2005 · 2.4K citations · Full text
Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells
Mahvash Zakikhani, Ryan J.O. Dowling, I. George Fantus et al. · Cancer Research · 2006 · 1K citations · Full text
New Users of Metformin Are at Low Risk of Incident Cancer
Gillian Libby, Louise A. Donnelly, Peter T. Donnan et al. · Diabetes Care · 2009 · 986 citations · Full text
Medicine, Oncology, Pharmacology +13